Sleeping pill reduces levels of Alzheimer’s proteins

KL2 alum, Brendan Lucey, MD is the senior author of a recent small, proof-of-concept study published in the Annals of Neurology (April 20). Lucey and a team of researchers at Washington University School of Medicine found that two doses of an FDA-approved sleeping pill reduced levels of Alzheimer’s proteins. The study hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease, although much more work needs to be done to confirm the viability of such an approach.